Cervical Cancer Case Study Eshetu Atenafu, Sandra Gardner, So-hee Kang, Anjela Tzontcheva University of Toronto Department of Public Health Sciences (Biostatistics)

Slides:



Advertisements
Similar presentations
Cervical Cancer Case Study Presented by: University of Guelph Baktiar Hasan Mark Kane Melanie Laframboise Michael Maschio Andy Quigley.
Advertisements

 DISCUSSION Number of resected lymph nodes in esophageal surgery has been previously discussed as for its probable impact on patients’ survival [4]. The.
Departments of Medicine and Biostatistics
Logistic Regression STA302 F 2014 See last slide for copyright information 1.
 - an important step in surgical staging for uterine cancer (FIGO 1988)  Stated as 
SHELBY ADDISON NEAL, MD MENTORS: WILLIAM T. CREASMAN, MD WHITNEY S. GRAYBILL, MD, MS Lymph-Vascular Space Invasion (LVSI) in Uterine Corpus Cancer What.
Cervical Cancer Keith Unger 2/24/06. Clinical History 47 yo F with vaginal bleeding and pelvic pain On exam, large cervical mass with parametrial involvement.
The SSC presented a data set on cervical cancer for analysis. Purpose of the analysis: determine the different attributes (covariates) for predicting relapse.
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.
Ductal Carcinoma in situ
Musculoskeletal Oncology Service, National Cancer Center Hospital Musculoskeletal Oncology Service, Keio University Hospital An Analysis of Clinicopathological.
Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.
Survival Analysis: From Square One to Square Two
Endometrial Carcinoma Fuat Demirkıran, MD Istanbul University, Cerrahpaşa School Of Medicine, OB&GYN Department, Gyn Oncology.
THE SIGNIFICANCE OF HISTOLOGICAL SUBSTAGING IN CURATIVE RESECTED T3 COLORECTAL CANCER Karl Mrak & Jörg Tschmelitsch Department of Surgery, Barmherzige.
Tang G et al. Proc SABCS 2010;Abstract S4-9.
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.
Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.
Dr Laura Bonnett Department of Biostatistics. UNDERSTANDING SURVIVAL ANALYSIS.
A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.
Failure of Treatment in Cervical Cancer Patients *Dr. Zohreh Yousefi fellow ship of gynecology oncology of Mashhad university Fatemeh Homaee, Marzieh.
Are there benefits from chemotherapy to early endometrial cancer
Lymphadenectomy in Epithelial Ovarian Cancer
Statistical approaches to analyse interval-censored data in a confirmatory trial Margareta Puu, AstraZeneca Mölndal 26 April 2006.
1 Introduction to medical survival analysis John Pearson Biostatistics consultant University of Otago Canterbury 7 October 2008.
D:/rg/folien/ms/ms-USA ppt F 1 Assessment of prediction error of risk prediction models Thomas Gerds and Martin Schumacher Institute of Medical.
Histopathological evaluation of lymphatic nodules in cancer of the uterine cervix Coordinators: First Author: Asist. Univ. Dr. Chira Liliana Stud. Bogdan.
An Assessment of Factors Affecting Outcome in Patients Presenting with Metastatic Soft Tissue Sarcoma Peter Ferguson MD1,2, Benjamin Deheshi MD1,2, Anthony.
Cervical Cancer Case Study Supervising Professor: Dr. P.D.M. Macdonald Team Members: Christine Calzonetti, Simo Goshev, Rongfang Gu, Shahidul Mohammad.
Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,
Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, MD 1, Bruce.
Survival Analysis 1 Always be contented, be grateful, be understanding and be compassionate.
on behalf of the ACOSOG Z4032 Investigators
Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.
Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,
FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,
Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.
J. Lujan, G. Valero, Q. Hernandez, A. Sanchez, M.D. Frutos and P. Parrilla. British Journal of Surgery, September 2009.
14 th Annual Meeting of the Connective Tissue Oncology Society November 13-15, 2008, London, UK Oliver Zivanovic, Mario M. Leitao, Alexia Iasonos, Lindsay.
Albert J. Chang, MD, PhD 1 Farrokh Dehdashti, MD 2 Perry W. Grigsby, MD, MS 1 Department of Radiation Oncology 1 Department of Radiology and Nuclear Medicine.
Local Recurrence Growth Rate Predicts Outcome In Locally Recurrent Retroperitoneal Liposarcoma James Park, MD, Li-Xuan Qin, PhD, Francesco Prete, MD Murray.
REGRESSION MODEL FITTING & IDENTIFICATION OF PROGNOSTIC FACTORS BISMA FAROOQI.
Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Gene Expression Signatures, Clinicopathological Features,
What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,
Radiological-histological size correlation in triple-negative breast cancer (TNBC) Abstract # 8254 C Thibault 1, M Gosset 2, F Chamming’s 3, M-A Lefrere-Belda.
ABSTRACT Purpose This retrospective review was conducted to determine if delay in the start of radiotherapy after conservative breast surgery had any detrimental.
Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.
Fig. 1: Regional abdominal lymph node dissection during 2-field LND. Fig. 2: full mobilisation of spleen and pancreatic tail to allow complete LND of.
ADVERSE PROGNOSTIC FACTORS IMPACTING SURVIVAL IN RESECTED INVASIVE, MUCINOUS CYSTADENOCARCINOMAS OF THE PANCREAS Stephen J. Ko 1, Michele M. Corsini 2,
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,
Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.
Uterine serous carcinoma is more aggressive than high-grade serous ovarian carcinoma: a retrospective study H. Nagano1, Y. Tachibana1, M. Kawakami1, M.
R. Michelle Sarin, MD Mentor: Jeffrey Fowler, MD
INTRODUCTION The SSC presented a data set on cervical cancer for analysis. Purpose of the analysis: determine the different attributes (covariates) for.
Survival Analysis: From Square One to Square Two Yin Bun Cheung, Ph.D. Paul Yip, Ph.D. Readings.
Compassionate People World Class Care
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Prognosis of younger patients in non-small cell lung cancer
Margin Status in Oral Cancer: Requirement for Reassessment
EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,
Management of endometrial cancer found on routine hysterectomy for benign disease Prof Dr M Anıl Onan MAY ANTALYA.
Factors predictive of prognosis after esophagectomy for squamous cell cancer  Houhuai Li, MD, PhD, Qingzhen Zhang, Lin Xu, MD, Yijiang Chen, Yongxiang.
Disease-specific survival
Published online September 20, 2017 by JAMA Surgery
Carcinoma of the esophagus: Prognostic significance of histologic type
Trends in survival from metastatic lung cancer in California,
Nadia Howlader, PhD National Cancer Institute
The SUV on 18F-FDG-PET/CT imaging as an independent predictor for overall survival and disease free survival after hepatectomy of Hepatocellular carcinoma(
Presentation transcript:

Cervical Cancer Case Study Eshetu Atenafu, Sandra Gardner, So-hee Kang, Anjela Tzontcheva University of Toronto Department of Public Health Sciences (Biostatistics) Acknowledgments: Professors P.Corey, J. Hsieh, W. Lou, J.Stafford

Outcome Variable Time to event calculated as recurrence date - surgery date; otherwise censored at death or last follow up date 4 cases where recurrence date > follow up date Decided there were no cases of left-censoring N=871, 68 recurrent events, 92% censored for a total of 3,573 person-years of follow up over the time period of 1984 to 2001

Covariate manipulation PELLYMPHAGE - 40SURGYR CLS 0 1 clear other MARGINS 0 1  1cm >1cm MAXDEPTH HIST 1 (SCC) HIST 3 (AC) HISTOLOG 0 1  3cm >3cm SIZE GRADE 2GRADE 3 GRADE 0 1 non treated ADJ_RAD

Covariate Summary (1) Age - median 40 years 3% with disease left after surgery 13% received radiation therapy 46% capillary-lymphatic space invasion 6% positive pelvic lymph nodes Histology –SCC 62%, AC 28%

Covariate Summary (2) Tumor grade (cell differentiation) –better 21%, moderate 52%, worst 27% Maximum depth of tumor –22% greater than 1 cm Tumor size –5% greater than 3 cm Median year of surgery is 1993

Methods Univariate log-rank tests Non-parametric survival trees (CART-SD) Semi-parametric (Cox regression) Parametric models (Exponential, Weibull, Log-normal)

Log-rank tests

Using all available data per variable

Complete data (n=549)

MAXDEPTH Loss of power concerns We are losing 23 recurrent event cases due to missing Maxdepth and only 4 for other missing covariates We developed models including and excluding Maxdepth Attempted imputation of all missing values (TRANSCAN and IMPUTE, Design and Hmisc S-plus/R libraries, F.Harrell)

Survival Trees Builds a binary decision tree and groups patients with similar prognosis Uses maximized version of Log-rank test to split the data into groups with different survival Advantages: non-parametric, “ranks” covariates by importance, captures interactions Disadvantages: non-interpretability of large trees, excludes cases with missing values

Survival Tree including Maxdepth

Survival Tree excluding Maxdepth

Comparisons of Cox models

Using imputed data

Using all available data per variable

Model Comparison

Exponential Model Prognostic Groups

Log-normal Model Prognostic Groups

Comparison of Prognostic Groups

Conclusions (1) Important prognostic factors are: – tumor size >3cm – capillary-lymphatic space invasion – positive pelvic lymph nodes – Squamous cell carcoma type histology Missing values and imputation issues with respect to maximum depth of tumor are of concern

Conclusions (2) We have selected 3 prognostic groups using non-parametric and parametric methods Parametric models appear to overestimate the 5 year survival probability for the high risk group Non-parametric and parametric 5 years survival estimates for the prognostic groups are similar, but the parametric models group fewer patients for high and moderate risk compared to the survival tree We are concerned, however, that the predictive ability of these models is poor.

Another Cohort Ishikawa H. et al. (1999) Prognostic Factors of Adenocarcinoma of the Uterine Cervix, Gynecologic Oncology 73:42-46 Nakanishi T. et al. (2000) A Comparison of Prognoses of Pathologic Stage 1b Adenocarinoma and Squamous Cell Carcinoma of the Uterine Cervix, Gynecologic Oncology 79: Nakanishi T. et al. (2000) The significance of tumor size in clinical stage 1b cervical cancer: Can a cut-off figure be determined?, International Journal of Gynecologic Cancer 10:

References LeBlanc, M. and Crowley J. (1993) Survival Trees by Goodness of Split. JASA 88: Segal, M. R.(1988) Regression Trees for Censored Data. Biometrics 44: Lausen B and Schumacher M. (1992) Maximally Selected Rank Statistics. Biometrics 48: Haupt G. Survival Trees in S-plus (library survcart demo)